Literature DB >> 7972209

Expression and function of the nerve growth factor receptor (TRK-A) in human neuroblastoma cell lines.

C G Azar1, N J Scavarda, A Nakagawara, G M Brodeur.   

Abstract

Nerve growth factor (NGF) is known to play a critical role in the differentiation and survival of normal sympathetic neurons through its interaction with a specific cell surface receptor. We analyzed ten well-characterized neuroblastoma cell lines for the expression and function of endogenous and exogenous p140TRK-A, and p75LNGFR. Exogenous LNGFR or TRK-A (or both) were introduced by transfection into three neuroblastoma cell lines. Transfected and untransfected neuroblastoma cell lines were analyzed by Northern analysis as well as tyrosine phosphorylation studies. Results indicate that endogenous TRK-A is expressed and/or p140TRK-A is phosphorylated in 10 of 10 cell lines. However, no other downstream responses to NGF stimulation (such as tyrosine phosphorylation of PLC gamma 1, PI-3 kinase, ERK1 and ERK2, induction of FOS and NGFI-A mRNAs, and neurite extension) were observed in the unresponsive cell lines. Transfection with p75LNGFR alone had no effect on responses to NGF stimulation. Three cell lines stably transfected with TRK-A exhibited early responses to NGF stimulation, but neurite extension was not observed. Our results indicate that endogenous TRK-A in non-responsive cell lines is either defective, or present in amounts below a threshold level required to elicit measurable responses to NGF. Furthermore, even after transfection with exogenous TRK-A, early responses were restored but later events such as neurite outgrowth did not occur, suggesting that downstream responsiveness is blocked as well.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972209

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  3 in total

1.  Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression.

Authors:  K Abdul-Wahab; D Corcoran; A Perachiotti; P D Darbre
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

Review 2.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Increased expression of trk proto-oncogene by gamma-interferon in human neuroblastoma cell lines.

Authors:  A Shikata; T Sugimoto; H Hosoi; Y Sotozono; T Shikata; T Sawada; L F Parada
Journal:  Jpn J Cancer Res       Date:  1994-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.